和鉑醫藥(02142.HK)HBM7008美國一期臨牀試驗完成首例患者首次給藥
和鉑醫藥(02142.HK)公佈,旗下產品B7H4x4-1BB雙特異性抗體(HBM7008)於美國進行的全球一期臨牀試驗,完成首例患者首次給藥。該研究將評估HBM7008對晚期實體瘤患者的安全性、耐受性、藥代動力學、藥效動力學及初步抗腫瘤活性。
公司表示,未來將持續推行全球創新及發展戰略以擴大業務合作及開發產品,全力投入HBM7008及HBM4003的全球開發計劃。
HBM7008爲一種針對腫瘤相關抗原B7H4x4-1BB的雙特異性抗體,在T細胞共刺激及抑制腫瘤生長方面的功效顯着。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.